0DZ0 Stock Overview
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
ChemoMetec A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.285.60 |
| 52 Week High | kr.553.50 |
| 52 Week Low | kr.257.60 |
| Beta | 1.2 |
| 1 Month Change | -32.55% |
| 3 Month Change | -23.39% |
| 1 Year Change | -21.33% |
| 3 Year Change | -58.49% |
| 5 Year Change | 65.57% |
| Change since IPO | 566.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0DZ0 | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -6.1% | -8.6% | -0.9% |
| 1Y | -21.3% | -45.7% | -1.8% |
Return vs Industry: 0DZ0 exceeded the UK Life Sciences industry which returned -45.7% over the past year.
Return vs Market: 0DZ0 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0DZ0 volatility | |
|---|---|
| 0DZ0 Average Weekly Movement | 11.7% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0DZ0's share price has been volatile over the past 3 months.
Volatility Over Time: 0DZ0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 171 | Martin Behrens | chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension.
ChemoMetec A/S Fundamentals Summary
| 0DZ0 fundamental statistics | |
|---|---|
| Market cap | kr.4.98b |
| Earnings (TTM) | kr.143.80m |
| Revenue (TTM) | kr.401.54m |
34.7x
P/E Ratio12.4x
P/S RatioIs 0DZ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0DZ0 income statement (TTM) | |
|---|---|
| Revenue | kr.401.54m |
| Cost of Revenue | kr.47.43m |
| Gross Profit | kr.354.11m |
| Other Expenses | kr.210.31m |
| Earnings | kr.143.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 8.26 |
| Gross Margin | 88.19% |
| Net Profit Margin | 35.81% |
| Debt/Equity Ratio | 0.2% |
How did 0DZ0 perform over the long term?
See historical performance and comparison